China's Dominance in Pharmaceutical Supply Poses National Security Risks
The United States currently produces only about 3% of the active pharmaceutical ingredients used globally, while China dominates the market with a staggering 45%. A study from Johns Hopkins indicates that over 60% of the essential components required by American manufacturers for antibiotics come from China. This situation not only reflects a troubling trade imbalance but also raises serious questions about national sovereignty and security.
The health of American citizens, including military personnel and children, is increasingly dependent on a foreign adversary that could potentially weaponize access to critical medications. The implications of this dependency are profound, as it places the safety of essential drugs in jeopardy.
Historically, the U.S. has seen a significant decline in its pharmaceutical manufacturing capabilities. In 1981, the country produced 25% of the world's pharmaceutical ingredients, but that figure has drastically fallen as manufacturing jobs have been offshored. The Council on Foreign Relations has described this situation as a "pharma choke point," highlighting the structural dependence on foreign sources for not just generic drugs but also advanced biologics.
China has already demonstrated a willingness to leverage its control over supply chains in other sectors, such as rare earth elements and semiconductors. This raises concerns about whether the Chinese Communist Party would treat pharmaceuticals any differently in a crisis, especially given its capacity to compromise the safety of medications.
Pharmaceutical Supply Chains and Fentanyl Crisis
Moreover, the same networks that supply American pharmacies with Chinese precursors are also implicated in the fentanyl crisis, with research indicating a coordinated supply chain involving Chinese suppliers and Mexican cartels. This connection underscores the dangers of relying on foreign sources for critical health supplies.
In response to these challenges, Congress has begun to take action. The BIOSECURE Act, enacted in December 2025, restricts federal procurement of biotechnology products from companies linked to foreign adversaries. Additionally, former President Donald Trump implemented tariffs aimed at curbing the synthetic opioid supply chain. While these legislative measures are steps in the right direction, they do not address the urgent need for domestic manufacturing capabilities.
Final Assessment
To effectively reduce reliance on China, substantial investment in U.S. pharmaceutical production is essential. States like Ohio are already positioning themselves as centers for advanced manufacturing, including semiconductors, and could similarly become hubs for pharmaceutical production. By incentivizing American companies to establish manufacturing facilities domestically, the U.S. can create jobs and enhance national security simultaneously.
The stakes are high: the health of the American population and the readiness of the military are at risk as long as the country remains dependent on a potential adversary for essential medications. The call to action is clear: invest in domestic pharmaceutical manufacturing to ensure medical independence and safeguard national security.
